Plex, you're not alone. There are many of us with sizeable accumulations that have been here since 2015 and have watched continuous missteps and missed targets. The basic science is looking better all of the time but management does virtually nothing to bolster the share price. A simple statement that the "super responders" from the original trial are stable and/or improving is the least that we should expect from Missling. The CTAD presentation obliquely hinted at it but there was nothing definitive from the company claiming success. It's either a partnership, or a buyout that will boost the SP and until then, all we can di is bitch on a message board.
Market Data 
Markets 
AI
